Exchange: NYSE·Updated 07:30 PM EDT
News
all
press releases
ResMed (RMD) Q4 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
More News
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.
Zacks
Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.
Zacks
Resmed's stock falls by 7% on soft FY27 outlook
Resmed's stock falls by 7% on soft FY27 outlook...
Yahoo! Finance: News
RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y
Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.
Zacks
Trade Desk Posts Downbeat Q2 Results, Joins Sezzle, Resmed, Ouster And Other Big Stocks Moving Lower In Friday's Pre-Market Session
US stock futures mixed, Nasdaq 100 futures up 100 points. Trade Desk Inc shares down 27.7% after weak Q2 results. Other stocks also lower premarket.read more...
Benzinga
ResMed (RMD) Q4 Earnings and Revenues Top Estimates
ResMed (RMD) delivered earnings and revenue surprises of +1.72% and +0.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Is INSP a Buy as Margins Improve but Reimbursement Risks Persist?
Inspire Medical's vast sleep apnea opportunity, rising margins and debt-free balance sheet support patience as reimbursement issues weigh on procedures.
Zacks
INSP's 28.1% Past-Month Rally Raises a Key Question for Investors
Inspire Medical shares jumped 28.1% as an earnings beat, raised 2026 guidance and estimate revisions offset reimbursement pressure.
Zacks
What to Expect From These 2 MedTech Stocks This Earnings Season?
Globus Medical and Resmed enter the earnings season with growth drivers intact despite tariff, inflation and hospital spending pressures.
Zacks

Advertisement|Remove ads.